Abstract：【Objective】To explore the clinical efficacy of perospirone combined with olanzapine in the treatment of schizophrenia and its influence on glucose and lipid metabolism.【Methods】A total of 102 schizophrenia patients admitted to our hospital from November 2020 to December 2023 were selected and divided into the observation group (treated with perospirone combined with olanzapine) and the control group (treated with olanzapine alone) by random number table method, with 51 cases in each group. The clinical efficacy after two months of treatment, symptom scores [Positive and Negative Symptom Scale (PANSS) scores] before and after two months of treatment, glucose and lipid metabolism levels [fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)], and cognitive function [Wisconsin Card Sorting Test (WCST) scores] were compared between the two groups. 【Results】 The total clinical effective rate of the observation group was 94.12% (48/51), which was higher than 78.43% (40/51) of the control group, and the difference was statistically significant (χ2=5.299, P<0.05). After treatment, the positive symptoms, negative symptoms, and general pathological scores of the two groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). After treatment, the serum FBG, HbA1c, TC, TG, and LDL-C levels of the two groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). After treatment, the number of completed classifications and total correct scores of the two groups were higher than those before treatment, and the observation group was higher than the control group, with statistically significant differences (P<0.05); the total response number, persistent error number, and total error scores of the two groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). 【Conclusion】Perospirone combined with olanzapine can effectively improve the clinical efficacy of schizophrenia patients, ameliorate their psychiatric symptoms, effectively regulate glucose and lipid metabolism levels, and help improve patients' cognitive function.
申贵玉, 黄焱, 黄海东, 谢清芳, 王能琨. 哌罗匹隆联合奥氮平治疗精神分裂症患者的临床疗效及其对糖脂代谢的影响[J]. 医学临床研究, 2025, 42(6): 997-999.
SHEN Guiyu, HUANG Yan, HUANG Haidong, et al. Clinical Efficacy of Perospirone Combined with Olanzapine in the Treatment of Schizophrenia and its Influence on Glucose and Lipid Metabolism. JOURNAL OF CLINICAL RESEARCH, 2025, 42(6): 997-999.
2025, Vol. 42 
